Search | Clinical Trials Finder

Conditions: End Stage Renal Disease, AV Fistula, Kidney Failure
Interventions: Venous Window Needle Guide; Device
Lead sponsor: Vital Access Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Fresno, California • Tulsa, Oklahoma

Conditions: Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Interventions: Velocity Percutaneous Arteriovenous Fistula; Device
Lead sponsor: Venova Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Dothan, Alabama • Concord, California • Riverside, California + 9 more

Conditions: Vein of Galen Malformations
Interventions: Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils; Device
Lead sponsor: Darren Orbach; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thrombosis
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Premature Infant, Chronic Respiratory Disease, Neuromuscular Diseases, Healthy, Bronchopulmonary Dysplasia, Pulmonary Vein Stenoses
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Days to 40 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cutaneous Venous Malformations
Interventions: QTORIN 3.9% rapamycin anhydrous gel; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more

Conditions: Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions: VT30; Drug
Lead sponsor: Venthera, Inc., a BridgeBio company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Interventions: Velocity pAVF System; Device
Lead sponsor: Venova Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Dothan, Alabama • Riverside, California • Jacksonville, Florida + 2 more

Conditions: Arteriovenous Fistula
Interventions: Covera Vascular Covered Stent; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • New Haven, Connecticut • Westmont, Illinois + 8 more

Conditions: Congenital Heart Defects
Interventions: Preserved umbilical vein as shunt/conduit; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 1 Day
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome, CLOVES Syndrome, Blue Rubber Bleb Nevus Syndrome
Interventions: High Intensity focused ultrasound; Device
Lead sponsor: Sonablate; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Darien, Connecticut

Conditions: May-Thurner Syndrome, Peripheral Vascular Disease, Venous Disease, Iliofemoral Occlusive Disease
Interventions: VENOVO™ Venous Stent; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Darien, Connecticut • New Haven, Connecticut • Davenport, Iowa + 9 more

Conditions: Congenital Venous Malformation
Interventions: Ethanol 96% Gel, Ethanol 98% Solution; Drug
Lead sponsor: Orfagen; Industry
Eligibility: 12 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
Interventions: KP-001, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypoplastic Left Heart Syndrome, Total Anomalous Pulmonary Venous Return, Truncus Arteriosus, Pulmonary Atresia With Ventricular Septal Defect, Transposition of the Great Arteries, Double Outlet Right Ventricle, Subpulmonary VSD, Tetralogy of Fallot, Double Outlet Right Ventricle With Subaortic Ventricular Septal Defect and Pulmonary Stenosis, Cardiopulmonary Bypass
Interventions: Normoxia (with controlled re-oxygenation), Standard of care ventilation; Other
Lead sponsor: University of Michigan; Other
Eligibility: Up to 29 Days
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Jonathan B. Zuckerman; Other
Eligibility: 6 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Antithrombin Deficiency, Congenital
Interventions: Recombinant Human Antithrombin (rhAT); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Marietta, Georgia • Charleston, South Carolina

Conditions: Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State, Venous Thromboembolism
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End Stage Renal Failure, Hemodialysis Access Failure, Arterio-venous Fistula
Interventions: One stage approach; Procedure
Lead sponsor: Tze-Woei Tan; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae

Vascular Lab Resource (VLR) Biorepository

Pivotal Study of the Velocity™ pAVF System

A Phase II Trial of Fetal Embolization for Vein of Galen Malformation

Sickle Cell Trait and the Risk of Venous Thromboembolism

Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

Natural History of Noncirrhotic Portal Hypertension

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery

Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery

BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease

Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period

Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

National Eye Institute Biorepository for Retinal Diseases

Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas